The drug’s manufacturer, Amgen Inc., says studies showed that Prolia improved bone mass and reduced the occurrence of new spine fractures in men with prostate cancer receiving androgen deprivation therapy and who did not have cancer spread to the bone. It also increased bone mass in women being treated with aromatase inhibitors for breast cancer.
The company says in a news release that Prolia is the “first-and-only” therapy approved by the FDA for cancer treatment bone loss in patients who have undergone hormone therapy.
A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.
The test supplements an elevated prostate specific antigen, or PSA, screening result, and could help some men delay or avoid a needle biopsy while pointing out men at highest risk for clinically significant prostate cancer.
The test looks for a genetic anomaly that occurs in about half of all prostate cancers, an instance of two genes changing places and fusing together. This gene fusion, TMPRSS2:ERG, is believed to cause prostate cancer. Studies in prostate tissues show that the gene fusion almost always indicates cancer. But because the gene fusion is present only half the time, the researchers also included another marker, PCA3. The combination was more predictive of cancer than either marker alone.
- U.S. cancer death rates continue to drop
- Lung cancer likely to overtake breast cancer as the main cause of cancer death among European women
- Squeezing Breasts Can Help Fight Breast Cancer
- Enzyme offers new therapeutic target for cancer drugs
- HPV Vaccine May Prevent Recurrence of Precancerous Conditions
- Survival Rate of Cancer Patients in Korea Ranked in the Top in the World
- Kids’ leukemia risk raised by dads who smoke
- Transplant recipients have a high risk of developing cancer
- CDC recommends that boys get vaccinated against HPV
- Cancer survivor population over 65 to increase over next decade